Complications of Thalassemia

Pathophysiology of complications

• Ineffective erythropoiesis drives bone marrow expansion.
• Medullary expansion causes characteristic skeletal deformities.
• Chronic tissue hypoxia stimulates erythropoietin production.
• Erythroid factor erythroferrone promotes excess intestinal iron absorption.
• Chronic red blood cell transfusions compound iron loading.
• Unbound iron deposits in visceral organs causing systemic hemosiderosis.

Hematological and reticuloendothelial complications

Hypersplenism and splenomegaly

• Chronic hemolysis and extramedullary hematopoiesis enlarge spleen.
• Progressive hypersplenism causes worsening anemia, leukopenia, and thrombocytopenia.
• Reduces survival of autologous and transfused red blood cells.
• Management:
  • Splenectomy indicated if annual packed red blood cell requirement exceeds 200-250 ml/kg/year.
  • Splenectomy indicated for symptomatic massive splenomegaly or severe cytopenias.
  • Pre-operative polyvalent pneumococcal, meningococcal, and haemophilus influenzae vaccines required at least 2 weeks prior.
  • Post-operative daily prophylactic oral penicillin (250 mg twice daily) mandatory.

Alloimmunization

• Development of antibodies against transfused red cell antigens.
• Incidence reaches 17.6%, primarily involving Kell and Rh groups.
• Management:
  • Perform extended red cell antigen phenotyping at diagnosis prior to initial transfusion.
  • Administer leukodepleted blood matched for ABO, Cc, Ee, and Kell antigens.

Skeletal complications

Bone deformities and osteopenia

• Frontal bossing, prominent malar eminences, depressed nasal bridge, maxillary prominence.
• Skull radiograph demonstrates classic hair-on-end appearance due to diploic space widening.
• Osteopenia and osteoporosis highly prevalent (approximately 60% in adults).
• Etiology remains multifactorial: medullary expansion, hypogonadism, nutritional deficits, chelator toxicity.
• Management:
  • Initiate annual bone densitometry screening by age 10.
  • Maintain pre-transfusion hemoglobin above 9.5 g/dl to suppress marrow expansion.
  • Administer calcium, vitamin d, and zinc supplementation.
  • Provide hormone replacement therapy for underlying gonadal insufficiency.
  • Administer bisphosphonates to inhibit osteoclast-mediated bone resorption.

Iron overload complications

Pathophysiology of Iron Overload

• Physiologic mechanism for excess iron excretion absent in humans.
• Transfusional iron load: 1 mL pure packed RBCs yields ~1 mg iron.
• Increased gastrointestinal iron absorption driven by ineffective erythropoiesis.
• Iron deposition sequence: Liver followed by endocrine organs, then heart.
• Morbidity: Cardiomyopathy (arrhythmias, heart failure), endocrinopathy (hypothyroidism, diabetes mellitus, hypogonadism, hypoparathyroidism), liver cirrhosis.

Cardiac complications

• Myocardial iron deposition causes heart failure and arrhythmias.
• Represents primary cause of mortality in thalassemia major.
• Diagnosis:
  • Cardiac T2 star magnetic resonance imaging.
  • Value less than 10 ms indicates severe iron loading and high cardiac risk.
• Management:
  • Maintain rigorous chelation adherence.
  • For cardiogenic shock: Initiate continuous intravenous deferoxamine (50-60 mg/kg/day).
  • Combine with oral deferiprone (75-99 mg/kg/day) for synergistic cardiac iron removal.
  • Utilize diuretics cautiously to prevent acute renal failure due to high baseline preload.

Endocrine complications

• Pituitary and glandular iron toxicity causes multiple endocrinopathies.
• Manifests as growth retardation, delayed puberty, hypogonadism, diabetes mellitus, hypothyroidism, and hypoparathyroidism.
• Management:
  • Monitor growth parameters quarterly.
  • Screen annually for fasting glucose, fructosamine, thyroid function, parathyroid hormone, and sex hormones starting age 10.
  • Administer exogenous hormone replacement (thyroxine, growth hormone, estrogen, testosterone) as indicated.

Hepatic complications

• Iron deposition causes liver fibrosis and eventual cirrhosis.
• Liver damage exacerbated by concomitant hepatitis b or c infection.
• Management:
  • Monitor liver iron concentration via magnetic resonance imaging or biopsy.
  • Adjust chelation to target liver iron concentration 2-5 mg/g dry weight.
  • Administer hepatitis a and b vaccinations.
  • Consult gastroenterology for antiviral management if hepatitis c positive.

Monitoring Iron Burden

• Serum Ferritin: Assess every 6 months. Target range 500-1500 ng/mL. Initiate chelation if >1000 ng/mL.
• Liver Iron Concentration (LIC): Noninvasive MRI (R2/R2*) preferred. Target LIC 2-5 mg Fe/g dry weight (dw). LIC >15 mg/g dw increases cardiac disease/death risk.
• Cardiac Iron (T2* MRI): Annual evaluation starting at age 10.
  • T2* >20 ms: Minimal cardiac iron loading (optimal goal).
  • T2* 10-19 ms: Mild-to-moderate loading; requires chelation intensification.
  • T2* <10 ms: Severe loading; high risk of arrhythmia/heart failure; requires aggressive dual therapy.

Chelation Agents

• Objective: Bind free extracellular iron, remove intracellular iron, reverse organ dysfunction.
• Initiation criteria: >10-20 transfusions, serum ferritin >1000 ng/mL on two occasions, or LIC >5 mg/g dw.

• Combination Therapy: Indicated for severe iron overload (e.g., elevated cardiac iron). Deferoxamine + Deferiprone or Deferoxamine + Deferasirox combinations utilized.

Vascular and pulmonary complications

Pulmonary hypertension and thrombosis

• Characterized by resting pulmonary artery systolic pressure greater than 25 mmhg.
• Screen utilizing echocardiography; tricuspid regurgitant jet velocity greater than 2.5 m/s indicates high risk.
• Splenectomy significantly exacerbates risk for both pulmonary hypertension and venous thromboembolism.
• Management:
  • Maintain adequate transfusion regimen.
  • Avoid splenectomy unless strictly indicated.
  • Consider prophylactic aspirin or anticoagulation for patients with additional thrombotic risk factors.

Other significant complications

Infections

• Highest risk follows splenectomy due to encapsulated organisms (streptococcus pneumoniae, haemophilus influenzae, neisseria meningitidis).
• Deferoxamine therapy increases susceptibility to yersinia enterocolitica sepsis.
• Management:
  • Educate families to seek immediate evaluation for fever.
  • In suspected septic shock, immediately hold all chelation therapy.
  • Administer aggressive fluid resuscitation and broad-spectrum intravenous antibiotics (third-generation cephalosporin plus aminoglycoside).

Cholelithiasis

• Chronic hemolysis increases bilirubin turnover causing pigmented gallstones.
• Management:
  • Perform abdominal ultrasound for symptomatic patients.
  • Laparoscopic cholecystectomy indicated for symptomatic disease.

Leg ulcers

• Occur over malleoli due to increased venous pressure from expanded bone marrow volume.
• Management:
  • Leg elevation, meticulous wound hygiene, elastic compression stockings.
  • Oral zinc sulfate supplementation.
  • Temporary intensive transfusion therapy for 3-6 months for refractory cases.